/
Oncology
Sarcoma
136
Pipeline Programs↗
201
Active Trials↗
91
Companies Involved↗
Sarcoma is a highly competitive landscape with 136 programs across 91 companies. The most active players are GSK. 31 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical27
Phase 121
Phase 257
Phase 331
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
99 of 126 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 126 classified programs, each share of the total. Modality classified for 96% of 136 pipeline programs.
Analysis
Trial Status
684
clinical trials
Completed304 · 44%
Recruiting118 · 17%
Unknown status72 · 11%
Terminated71 · 10%
Active, not recruiting55 · 8%
Not yet recruiting26 · 4%
Other38 · 6%
Clinical Trials
Trial Activity
684 trials
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma
Recruiting·—·Preclinical·NCT06797999·270 enrolled
Page 1 of 46
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)